Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2789-2790.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shpall, E.
Right arrow Articles by Champlin, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shpall, E.
Right arrow Articles by Champlin, R.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

TRANSPLANTATION

Comment on Brunstein et al, page 3064

Are 2 cords better than 1?

Elizabeth Shpall, Marcos de Lima, Roy Jones, and Richard Champlin

M. D. ANDERSON DEPARTMENT OF STEM CELL TRANSPLANTATION AND CELLULAR THERAPY

In this issue of Blood, Brunstein and colleagues describe the use of nonmyeloablative conditioning and double umbilical cord blood transplantation (UCBT) for treatment of adult patients.

UCBT is an attractive source of hematopoietic progenitor cells that might be broadly applicable to patients lacking acceptable donors. A major limitation of UCBT has been the small cell dose and resulting delayed time to engraftment in adults. The data in this report convincingly demonstrate that rapid neutrophil recovery with ultimate predominance of a single cord can be achieved with this technique. Although the follow-up is short, the favorable relapse-free survival following a nonmyeloablative regimen suggests a potent UCB-mediated graft-versus-tumor effect. A single very large UCB unit meeting the protocol transplant standard was found and used in only 17 of the 110 patients, underscoring the limitations of comparing transplantation of 1 versus 2 cords in this study. Nevertheless, as suggested by the authors, it appears unlikely that a randomized comparison of unmanipulated single versus double UCBT will be performed for adults, in view of this data. Double UCBT seems likely to emerge as a standard to which newer adult UCBT techniques will be compared in the future.


Figure 1
View larger version (14K):
[in this window]
[in a new window]

 
Cumulative proportion of 3-year event-free survival (A) and overall survival (B) for patients receiving either 1 (—) or 2 ({blacksquare}{blacksquare}{blacksquare}) UCB unit transplants after a nonmyeloablative conditioning regimen. See the complete figure in the article beginning on page 3064.

 
A number of important questions continue to surround double UCBT. How important is the increasing degree of HLA matching both to the recipient and between the 2 cords? It is likely that the rapidly enlarging CB banks will make tighter matching routinely possible. Since 2 cords may produce a somewhat higher incidence of acute graft-versus-host disease (GVHD) in adults than single CBT, is there an increased risk of infection or other GVHD complications using this technique? Should GVHD be modulated (as done in this study) using high-dose antithymocyte globulin (ATG) or similar techniques, and what is the association with risk of tumor relapse? How important is the long-term thrombocytopenia seen in a subset of these patients, and can new technologies overcome this problem? Why did younger patients in this study fare more poorly than older patients with favorable clinical features? Do they need more dose-intensive therapy? How important is careful patient selection, and to what degree does such selection limit the generalizability of the results of this trial?

This report, and other studies,13 provide increasing evidence that UCBT represents a practical and important advance in hematopoietic-cell transplantation. The improvement in engraftment and event-free survival reported here provides much encouragement for wider exploration of this technique. Issues such as the use of ex vivo UCB manipulation,4 in vivo administration of newer thrombopoietin-type agents,5 and optimization of immune suppression to modulate GVHD can now be explored in a more meaningful way. The relationship between preparative regimen intensity, GVHD, UCB engraftment, and toxicities requires investigation, as many patients may need more intensive chemotherapy regimens for tumor eradication. Disease-specific investigations will become an important part of future studies. Finally, some would argue that these results are sufficiently promising that randomized comparisons between UCBT and, for example, haploidentical peripheral blood transplantation will soon be warranted. The outcomes of the patients in this prospective report provide some of the most meaningful adult UCBT data to date, and can be used to benchmark future studies exploring this maturing technique in adults.

Footnotes

Conflict-of-interest disclosure: The authors declare no competing financial interests. {blacksquare}

REFERENCES

  1. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276–2285.[Abstract/Free Full Text]

  2. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351:2265–2275.[Abstract/Free Full Text]

  3. Barker JN, Davies SM, DeFor T, et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97:2957–2961.[Abstract/Free Full Text]

  4. Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002; 8:368–376.[CrossRef][Medline] [Order article via Infotrieve]

  5. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672–1681.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
Claudio G. Brunstein, Juliet N. Barker, Daniel J. Weisdorf, Todd E. DeFor, Jeffrey S. Miller, Bruce R. Blazar, Philip B. McGlave, and John E. Wagner
Blood 2007 110: 3064-3070. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shpall, E.
Right arrow Articles by Champlin, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shpall, E.
Right arrow Articles by Champlin, R.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020